SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX

Core Viewpoint - HilleVax, Inc. is under investigation for potential securities fraud and unlawful business practices following the failure of its clinical trial for HIL-214, which did not meet its primary efficacy endpoint [1][2]. Group 1: Clinical Trial Results - On July 8, 2024, HilleVax announced topline data from the NEST-IN1 Phase 2b clinical trial, which evaluated the efficacy, safety, and immunogenicity of HIL-214 in infants [2]. - The trial did not meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis events due to GI.1 or GII.4 norovirus genotypes, and no clinical benefit was observed across secondary endpoints [2]. Group 2: Stock Market Reaction - Following the announcement of the clinical trial results, HilleVax's stock price fell by $12.42 per share, representing an 88.3% decline, closing at $1.64 per share on July 8, 2024 [4]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of HilleVax investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].